Approval · Notice of Compliance 30000 · 2023
REPAGLINIDE: Notice of Compliance 30000
Issued January 27, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30000
- Date
- January 27, 2023
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Administrative: Labelling Update (to Match Licensor)
- Canadian reference product
- GLUCONORM (Novo Nordisk Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REPAGLINIDE | Not yet assigned | — |
Medicinal ingredients
- REPAGLINIDE 0.5 MG per TAB
- REPAGLINIDE 1 MG per TAB
- REPAGLINIDE 2 MG per TAB